白蛋白结合型紫杉醇治疗复发性卵巢癌及输卵管癌和原发腹膜腺癌的近期疗效和安全性观察

发布时间：2018-03-31 04:03

  本文选题：白蛋白结合型紫杉醇　切入点：复发性卵巢癌　出处：《实用妇产科杂志》2015年09期

【摘要】：目的:对白蛋白结合型紫杉醇(NAB-P)治疗复发性卵巢癌、输卵管癌及原发腹膜腺癌的近期疗效及安全性进行分析。方法:收集复发性卵巢癌、输卵管癌及原发腹膜腺癌患者共21例,分析NABP为基础的化疗方案、治疗过程中血清CA125检测值、相关临床及药物不良反应资料。采用实体瘤疗效评价标准(RECIST)以及国际妇癌协会(GCIG)的CA125反应评价标准评估疗效。通过治疗方案的中断情况及患者发生的不良反应评估以NAB-P为基础方案的耐受性。结果:21例患者中,无铂间期6个月者占33.3%(7/21),无铂间期6个月者占66.7%(14/21)。6例患者在NAB-P基础方案治疗后出现缓解,有效率为28.6%(6/21)。CA125升高患者的有效率为33.3%(6/18),均为完全缓解。无铂间期6个月者的有效率为42.9%(3/7),无铂间期6个月者的有效率为21.4%(3/14),两者比较差异无统计学意义(P0.05)。仅4例患者因血小板减少Ⅲ度、白细胞减少Ⅲ~Ⅳ度或中性粒细胞减少Ⅲ~Ⅳ度停止化疗。结论:NAB-P为基础的化疗方案在接受过多线化疗的卵巢癌、输卵管癌及原发腹膜腺癌患者中有一定的临床疗效,患者的总体耐受性较好,可作为该类患者的治疗选择。
[Abstract]:Objective: to analyze the short-term efficacy and safety of albumin bound paclitaxel (NAB-P) in the treatment of recurrent ovarian cancer, fallopian tube carcinoma and primary peritoneal adenocarcinoma. Methods: 21 patients with recurrent ovarian cancer, fallopian tube carcinoma and primary peritoneal adenocarcinoma were collected. Analysis of NABP based chemotherapy regimen, serum CA125 detection value during the course of treatment, Relevant clinical and adverse drug reaction data. CA125 response evaluation criteria were used to evaluate the efficacy of solid tumor evaluation criteria (RECIST) and the International Women's Cancer Association (IGC). The tolerance of the NAB-P based scheme was evaluated. Results in 21 patients with NAB-P, The patients with no platinum interval of 6 months accounted for 33.3% and those without platinum interval for 6 months accounted for 66.7% 14 / 21.6 cases of remission after the treatment of basic NAB-P regimen. The effective rate of patients with elevated 28.6%(6/21).CA125 was 33.3 / 18%, which was completely relieved. The effective rate of patients with no platinum interval of 6 months was 42.9 / 7, and the effective rate of patients without platinum interval of 6 months was 21.440 / 3 / 14. There was no significant difference between the two groups (P 0.05). Only 4 patients had thrombocytopenia 鈪，

本文编号：1689042